These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27053057)

  • 21. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Course of platelet miRNAs after cessation of P2Y12 antagonists.
    Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
    Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Cattaneo GJ; Podda GM; Cattaneo M
    Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
    Khan N; Cox AR; Cotton JM
    Thromb Res; 2016 Jul; 143():141-8. PubMed ID: 27259210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
    Capodanno D; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2016 Jul; 14(7):811-20. PubMed ID: 26953527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repetitive remote occlusion (RRO) stimulates eNOS-dependent blood flow and collateral expansion in hindlimb ischemia.
    Schuler D; Sansone R; Nicolaus C; Kelm M; Heiss C
    Free Radic Biol Med; 2018 Dec; 129():520-531. PubMed ID: 30336250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tailored P2Y
    Janssen PWA; Bergmeijer TO; Vos GA; Kelder JC; Qaderdan K; Godschalk TC; Breet NJ; Deneer VHM; Hackeng CM; Ten Berg JM
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1201-1210. PubMed ID: 31197411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
    Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Antiplatelet Therapy in Coronary Disease.
    Falcão Gonçalves P; Menezes Falcão L
    Am J Ther; 2017; 24(6):e744-e750. PubMed ID: 26752652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
    Ariotti S; Ortega-Paz L; van Leeuwen M; Brugaletta S; Leonardi S; Akkerhuis KM; Rimoldi SF; Janssens G; Gianni U; van den Berge JC; Karagiannis A; Windecker S; Valgimigli M;
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1576-1586. PubMed ID: 29805112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of cessation of 2nd generation P
    Witberg G; Bathish J; Bental T; Leshem-Lev D; Assali A; Kornowski R; Lev E
    J Thromb Thrombolysis; 2018 Oct; 46(3):351-358. PubMed ID: 29922880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prasugrel anti-ischemic effect in rats: Modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories.
    Gomaa AA; El-Abhar HS; Abdallah DM; Awad AS; Soubh AA
    Toxicol Appl Pharmacol; 2021 Sep; 426():115635. PubMed ID: 34174262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
    Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
    Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.
    Hashimoto M; Sugidachi A; Isobe T; Niitsu Y; Ogawa T; Jakubowski JA; Asai F
    Biochem Pharmacol; 2007 Oct; 74(7):1003-9. PubMed ID: 17681285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.